← All Immunitybio, INC filings

Immunitybio, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
IBRX
Immunitybio, INC
DEF 14C: ImmunityBio Boosts Authorized Shares for Future Funding
ImmunityBio, Inc. has increased its authorized common stock to 1.65 billion shares to secure future funding and meet existing commitments.
NASDAQ
IBRX
Immunitybio, INC
DEFA14A: ImmunityBio, Inc. Announces 2025 Annual Meeting and Proxy Materials
ImmunityBio, Inc. is holding its 2025 Annual Meeting on June 18, 2025, and has released proxy materials for stockholders to review and vote on key proposals.
NASDAQ
IBRX
Immunitybio, INC
DEF 14A: ImmunityBio Sets Date for 2025 Annual Stockholders Meeting, Proposes Equity Incentive Plan
ImmunityBio announces its 2025 annual meeting of stockholders to be held virtually on June 18, 2025, to vote on director elections, an equity incentive plan, and auditor ratification.
NASDAQ
IBRX
Immunitybio, INC
DEFA14A: ImmunityBio, Inc. to Hold Annual Meeting, Seeks Stockholder Votes on Key Proposals
ImmunityBio, Inc. is holding its annual meeting on June 11, 2024, and is soliciting stockholder votes on director elections, an equity incentive plan amendment, executive compensation, and auditor ratification.
NASDAQ
IBRX
Immunitybio, INC
DEF 14A: ImmunityBio Seeks Stockholder Approval for Equity Incentive Plan Amendment at 2024 Annual Meeting
ImmunityBio's upcoming annual meeting on June 11, 2024, will include proposals for director elections, an equity incentive plan amendment, executive compensation approval, and auditor ratification.